Home » Stocks » NTRA

Natera, Inc. (NTRA)

Stock Price: $116.09 USD 7.33 (6.74%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $116.00 -0.09 (-0.08%) Feb 26, 7:34 PM
Market Cap 9.91B
Revenue (ttm) 391.01M
Net Income (ttm) -229.74M
Shares Out 81.01M
EPS (ttm) -2.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $116.09
Previous Close $108.76
Change ($) 7.33
Change (%) 6.74%
Day's Open 115.08
Day's Range 108.29 - 123.78
Day's Volume 1,436,689
52-Week Range 16.87 - 127.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Proactive Investors - 2 days ago

Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N), a supplier of vegetarian meat substitutes, sports and energy bars, and hemp-based products, has appealed the Federal Cou...

Benzinga - 3 days ago

Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 93.48% year over year to ($0.89), which missed the ...

Zacks Investment Research - 4 days ago

Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 1 week ago

Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 1 week ago

MENLO PARK, Calif. & SAN CARLOS, Calif.--(BUSINESS WIRE)---- $NTRA #PrecisionOncology--Natera and Personalis Partner for Personalized Monitoring in Oncology

InvestorPlace - 2 weeks ago

Some medical stocks gained momentum because of the pandemic, while others focus on high-reward challenges like cancer treatment. The post 7 Healthy Medical Stocks to Buy appeared first on Inve...

Other stocks mentioned: AMED, CRDF, FLGT, GHSI, OMI, TDOC
PRNewsWire - 3 weeks ago

SAN CARLOS, Calif., Feb. 3, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual P...

PRNewsWire - 1 month ago

SAN CARLOS, Calif., Jan. 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-...

PRNewsWire - 1 month ago

SAN CARLOS, Calif., Jan. 14, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on the Pro...

PRNewsWire - 1 month ago

SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalize...

The Motley Fool - 1 month ago

These winners are positioned for gains even after COVID.

Other stocks mentioned: FLGT, GNMK, AWH, CODX
PRNewsWire - 1 month ago

SAN CARLOS, Calif., Jan. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at ...

PRNewsWire - 2 months ago

SAN CARLOS, Calif., Dec. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office gra...

Seeking Alpha - 2 months ago

Increased adoption and expansion of products resulting in significant rises in volume. Producing meaningful improvements in revenues and costs per unit.

PRNewsWire - 2 months ago

SAN CARLOS, Calif., Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United S...

PRNewsWire - 3 months ago

SAN CARLOS, Calif., Nov. 30, 2020 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of Oncology,...

Seeking Alpha - 3 months ago

Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.

Other stocks mentioned: EXAS, GH, ILMN, PSNL
PRNewsWire - 3 months ago

SAN CARLOS, Calif., Nov. 12, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the ...

Insider Monkey - 3 months ago

In this article we will take a look at whether hedge funds think Natera Inc (NASDAQ:NTRA) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving ...

PRNewsWire - 3 months ago

SAN CARLOS, Calif., Nov. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on i...

Seeking Alpha - 3 months ago

Natera, Inc. (NTRA) CEO Steve Chapman on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 4 months ago

SAN CARLOS, Calif., Oct. 30, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prena...

PRNewsWire - 4 months ago

SAN CARLOS, Calif., Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third ...

PRNewsWire - 4 months ago

SAN CARLOS, Calif., Oct. 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that a major health plan has extended cover...

Zacks Investment Research - 4 months ago

Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

SAN CARLOS, Calif., Oct. 8, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Centene, a major healthcare insurance c...

PRNewsWire - 4 months ago

SAN CARLOS, Calif. and LOS ANGELES, Oct. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has teamed up with the George Lo...

PRNewsWire - 4 months ago

SAN CARLOS, Calif., Oct. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reports that the U.S. District Court of Delaware has r...

PRNewsWire - 4 months ago

SAN CARLOS, Calif., Oct. 2, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) ...

Zacks Investment Research - 4 months ago

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.

Other stocks mentioned: BDX, EXAS, GH, ILMN, NVTA, QDEL
Zacks Investment Research - 5 months ago

Natera (NTRA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 24, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program...

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personaliz...

Seeking Alpha - 5 months ago

For this report, we analyzed the portfolios of the 13 small-cap growth investment managers with the best 10-year performance records.

Other stocks mentioned: ALRM, AVLR, ETSY, EYE, FIVN, FRPT, IRTC, LITE, MIME, PLMR, QTWO, SILK, SPSC
PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 14, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 10, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 10, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 9, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 3, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 2, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 5 months ago

SAN CARLOS, Calif., Sept. 1, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 6 months ago

SAN CARLOS, Calif., Aug. 27, 2020 /PRNewswire/ -- Natera, Inc.

Investors Business Daily - 6 months ago

Natera shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. The post Stock Upgrades: Natera Shows Rising Relative Strength appeared first on Investor's Busi...

PRNewsWire - 6 months ago

SAN CARLOS, Calif., Aug. 18, 2020 /PRNewswire/ -- Natera, Inc.

PRNewsWire - 6 months ago

SAN CARLOS, Calif., Aug. 7, 2020 /PRNewswire/ -- Natera, Inc.

Seeking Alpha - 6 months ago

Natera, Inc. (NTRA) CEO Steve Chapman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Natera (NTRA) delivered earnings and revenue surprises of -21.05% and 17.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 6 months ago

SAN CARLOS, Calif., Aug. 5, 2020 /PRNewswire/ -- Natera, Inc.

About NTRA

Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 2, 2015
Stock Exchange
NASDAQ
Ticker Symbol
NTRA
Full Company Profile

Financial Performance

In 2020, Natera's revenue was $391.01 million, an increase of 29.33% compared to the previous year's $302.33 million. Losses were -$229.74 million, 84.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Natera stock is "Strong Buy." The 12-month stock price forecast is 122.78, which is an increase of 5.76% from the latest price.

Price Target
$122.78
(5.76% upside)
Analyst Consensus: Strong Buy